肾癌药物市场 - 按癌症类型、治疗方法、药物类别、给药途径、配销通路和全球预测

在药物开发和治疗方案中越来越重视以患者为中心的方法的推动下，肾癌药物市场规模从 2024 年到 2032 年的复合年增长率将达到 5.6%。

基因组分析和生物标记研究的最新进展正在为肾癌治疗的个人化医疗铺平道路。例如，2023年12月，HIF-2a抑制剂Belzutifan被美国FDA核准用于治疗先前接受过抗血管新生疗法和免疫检查点抑制剂治疗的晚期肾癌患者。开发具有成本效益的治疗方法、实施定价策略和扩大保险覆盖范围的持续努力也将影响市场的成长。

肾癌药物产业分为癌症类型、治疗方法、药物类别、给药途径、配销通路和地区。

按癌症类型划分，肾母细胞瘤细分市场的行业价值将在2024 年至2032 年间出现利润丰厚的增长。 。为此，多家製药公司正在开发和销售针对儿童的药物。治疗儿科癌症的需求不断增长，导致医疗基础设施（例如专门的儿科肿瘤中心）得到改善，从而促进了该细分市场的成长。

就给药途径而言，预计到2032 年，静脉注射肾癌药物的市场规模将显着扩大。中获得更好的疗效。肿瘤学家也更喜欢为某些患者提供静脉注射药物，尤其是那些由于口服药物的副作用或其他医疗状况而难以使用口服药物的患者。

到 2032 年，在治疗方案的快速进步和消费者意识不断提高的带动下，亚太地区肾癌药物产业份额将实现大幅复合年增长率。对临床试验和研究计划的大量投资正在导致针对该地区患者基因特征的创新药物的开发。肾癌发病率的飙升以及随后对有效药物的需求以及不断增长的监管支持将有利于区域产品的吸收。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 肾癌盛行率增加
    • 提高意识和早期诊断倡议
    • 技术进步
  • 产业陷阱与挑战
    • 治疗费用高
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按癌症类型，2021 - 2032 年

• 主要趋势
• 肾臟细胞癌（RCC）
• 移行细胞癌
• 肾母细胞瘤
• 肾臟肉瘤

第 6 章：市场估计与预测：按治疗方式，2021 - 2032 年

• 主要趋势
• 标靶治疗
• 免疫疗法
• 化疗
• 其他疗法

第 7 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 血管新生抑制剂
• 单株抗体
• mTOR抑制剂
• 细胞激素免疫疗法（IL-2）
• 其他药物类别

第 8 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 口服
• 静脉
• 皮下

第 9 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 医院药房
• 砖块和灰浆
• 电子商务

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Active Biotech AB
• Amgen, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• GSK plc
• Helsinn Healthcare SA
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG

Kidney Cancer Drugs Market size will record 5.6% CAGR from 2024-2032, driven by the growing emphasis on patient-centric approaches in drug development and treatment protocols.

The recent advances in genomic profiling and biomarker research are paving the way for personalized medicine in kidney cancer treatment. For instance, in December 2023, Belzutifan, a HIF-2a inhibitor, was approved by the U.S. FDA for treating patients suffering from advanced kidney cancer that was previously treated with anti-angiogenic therapies and immune checkpoint inhibitors. The rising efforts to develop cost-effective treatments, implement pricing strategies, and expand insurance coverage will also influence the market growth.

The kidney cancer drugs industry is segmented into cancer type, therapy, drug class, route of administration, distribution channel, and region.

By cancer type, the industry value from the Wilms tumor segment will register lucrative growth between 2024 and 2032. As Wilms tumor is a pediatric cancer, its treatment creates a specific demand for pediatric oncology drugs. To that end, several pharmaceutical companies are developing and marketing drugs tailored for children. This surging need to treat pediatric cancers is leading to improvements in healthcare infrastructure, such as specialized pediatric oncology centers, adding to the segment growth.

In terms of route of administration, the kidney cancer drugs market size from the intravenous segment is expected to record significant expansion through 2032. Intravenous (IV) administration allows effective delivery of higher concentrations of the drugs directly into the bloodstream, leading to better efficacy in treating advanced and metastatic kidney cancer. Oncologists also prefer IV drugs for certain patients, especially those who have difficulty with oral medications given their side effects or other medical conditions.

Asia Pacific kidney cancer drugs industry share will register substantial CAGR through 2032, led by rapid advances in treatment options and the increasing consumer awareness. Significant investments in clinical trials and research initiatives are leading to the development of innovative drugs tailored to the genetic profiles of patients in the region. The surging rate of kidney cancer incidence and the subsequent demand for effective drugs along with the growing regulatory support will favor the regional product uptake.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of kidney cancer
    • 3.2.1.2 Rising awareness and early diagnosis initiatives
    • 3.2.1.3 Technological advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Renal cell carcinoma (RCC)
• 5.3 Transitional cell cancer
• 5.4 Wilms tumor
• 5.5 Renal sarcoma

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Targeted therapy
• 6.3 Immunotherapy
• 6.4 Chemotherapy
• 6.5 Other therapies

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Angiogenesis inhibitors
• 7.3 Monoclonal antibodies
• 7.4 mTOR inhibitors
• 7.5 Cytokine immunotherapy (IL-2)
• 7.6 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Intravenous
• 8.4 Subcutaneous

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Brick and mortar
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Active Biotech AB
• 11.2 Amgen, Inc.
• 11.3 Astellas Pharma Inc.
• 11.4 AstraZeneca PLC
• 11.5 Bayer AG
• 11.6 Bristol-Myers Squibb Company
• 11.7 Eisai Co., Ltd.
• 11.8 Exelixis, Inc.
• 11.9 F. Hoffmann-La Roche Ltd.
• 11.10 Genentech, Inc.
• 11.11 GSK plc
• 11.12 Helsinn Healthcare SA
• 11.13 Johnson & Johnson Services, Inc.
• 11.14 Merck & Co., Inc.
• 11.15 Novartis AG